Table 1 Summary of cardiomyocyte derivation from various origins
From: Uses of cardiomyocytes generated from induced pluripotent stem cells
Study | Species | Cell type | Method of differentiation | Factors to enhance differentiation | Purification of cardiomyocytes | Application |
|---|---|---|---|---|---|---|
Doetschman et al. [5] | Mouse | ESC or EC | 15% FCS in suspension culture | - | - | - |
Maltsev et al. [21] | Mouse | ESC | 20% FCS in suspension culture | - | - | - |
Maltsev et al. [22] | Mouse | ESC | 20% FCS in suspension culture | - | Isolation by cutting the beating area of EBs | - |
Klug et al. [19] | Mouse | ESC | 10% FCS in suspension culture | No LIF | Microdissecting the beating area of EBs or selection by α-MHC-neo transgene | - |
Wobus et al. [8] | Mouse | ESC | 20% FCS in suspension culture | RA | Selection by MLC-2v-β-gal-neo transgene | - |
Kolossov et al. [20] | Mouse | ESC | 20% FCS in suspension culture | - | Selection by α-actin-GFP transgene | - |
Kehat et al. [29] | Human | ESC | 20% FCS in suspension culture | DMSO | - | - |
Xu et al. [28] | Human | ESC | 20% FCS in suspension culture | 5-aza-dC | Separation by Percoll density centrifugation | Test response of CMs to several pharmacological agents |
Mummery et al. [34] | Human | ESC | Co-culture with VE-like END-2 cells | - | - | - |
He et al. [30] | Human | ESC | 15% FCS in suspension culture | - | - | Characterizing multiple types of CMs by action potential measuring |
Segev et al. [37] | Human | ESC | 20% FCS in suspension culture | - | - | - |
Passier et al. [35] | Human | ESC | 0 to 20% FCS in suspension and co-culture with VE-like END-2 cells, in the absence of ITS or in the presence of ascorbic acid | - | - | - |
Yoon et al. [31] | Human | ESC | 20% FCS in hanging drop culture | 5-aza-dC | - | - |
Schwanke et al. [43] | Monkey | ESC | 20% FCS in suspension culture | - | - | - |
Abdelalim et al. [42] | Monkey | ESC | 15% FCS in hanging drop culture | - | Microdissecting the beating area of EBs | - |
Dai et al. [76] | Human | ESC | Serum-free END-2 cell-conditioned medium | - | - | CM injection into ischemic rat left ventricle |
Huber et al. [38] | Human | ESC | 20% FCS in suspension culture | - | Selection by hMLC-2v-GFP-neo transgene and FACS sorting for GFP-positive cells | Formation of stable myocardial cell grafts after in vivo cell transplantation |
Anderson et al. [39] | Human | ESC | 20% FCS in suspension culture | - | Both negative selection by HSVtk/GCV and positive selection by α-MHC-GFP-PAC transgene | - |
Narazaki et al. [49] | Mouse | iPSC | 10% FCS in suspension culture | No LIF | - | - |
Mauritz et al. [47] | Mouse | iPSC | 15% FCS in hanging drop culture | - | - | - |
Schenke-Layland et al. [48] | Mouse | iPSC | 10% FCS in suspension culture | No LIF | - | - |
Yang et al. [36] | Human | ESC | Serum-free medium | BMP4, bFGF, activin A, DKK1, VEGF | Selection by Flk1 FACS sorting | - |
Takei et al. [33] | Human | ESC | 20% FCS in suspension culture | BMP4 | - | - |
Zhang et al. [50] | Human | iPSC | 20% FCS in suspension culture | - | - | - |
Zwi et al. [51] | Human | iPSC | 20% FCS in suspension culture | - | - | Serving as in vitro platform for pharmacological QT screening |
Ieda et al. [80] | Mouse | Fibroblast | Fibroblasts from αMHC-GFP transgenic mice were transduced with viruses carrying TFs (Gata4, Mef2c, Tbx5) | - | - | Direct reprogramming of fibroblasts into CMs |
Carvajal-Vergara et al. [66] | Human | iPSC | Serum-free medium | BMP4, bFGF, activin A, DKK1, VEGF | Selection by Flk1 FACS sorting | In vitro LEOPARD syndrome modeling |
Moretti et al. [71] | Human | iPSC | 20% FCS in suspension culture | - | Microdissecting the beating area of EBs | In vitro LQTS modeling |
Itzhaki et al. [72] | Human | iPSC | 20% FCS in suspension culture | - | - | In vitro LQTS modeling |
Yazawa et al. [73] | Human | iPSC | 20% FCS in suspension culture | Wnt3a | - | In vitro Timothy syndrome modeling |
Efe et al. [82] | Mouse | Fibroblast | Fibroblasts harboring a Nebulette-LacZ transgene were transduced with viruses carrying TFs (Oct4, Sox2, Klf4) | No LIF, but plus BMP4 or JI1 | - | Direct reprogramming of fibroblasts into CMs |
Cao et al. [41] | Rat | ESC | 10% FCS in hanging drop culture | Small molecule inhibitor | - | - |